A prospective study to evaluate the gender prediction of blastocysts by using cell-free DNA within a culture medium

Somayeh Barzanouni1 M.D., Farideh Moramezi1,2 M.D., Mahvash Zargar1 M.D., Hamid Galehdari3 Ph.D., Masoud Hemadi2 Ph.D.

1Department of Obstetrics and Gynecology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
2Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
3Department of Genetics, Faculty of Sciences, Shahid Chamran University of Ahvaz, Ahvaz, Iran.

Abstract

Background: Preimplantation genetic diagnosis (PGD) has been used as an option for couples with the possibility of having a baby with a genetic disorder. The common method for performing this test involves isolating 1 cell from day 3 or a few cells from day 5 embryos and performing genetic studies on the cell-extracted DNA. This method is invasive and can cause abortion after implantation in the uterus. Because of this, 2 noninvasive methods for performing a PGD have been studied: PGD using blastocyst fluid and PGD using embryo culture medium.

Objective: The aim of this study is to determine the sensitivity of the polymerase chain reaction (PCR) technique to detect the Y chromosome using cell-free DNA within a culture medium for gender prediction of blastocysts.

Materials and Methods: In this study, the gender of 30 embryos on day 5 was determined using embryonic DNA extraction from the culture medium and the PCR technique to evaluate the sex-determining region Y and fragile X mental retardation genes. Then, the accuracy was assessed using ultrasound.

Results: The results of the PCR technique showed that 7 embryos were male, but an ultrasound revealed that 13 were male.

Conclusion: The given results indicated that, because of the low amount of DNA extracted from the culture medium, the diagnosis of the existence of the Y chromosome by this method is still not accurate enough for detecting the gender of the embryo.

Key words: Preimplantation diagnosis, Embryo implantation, Culture media, Blastocyst, Polymerase chain reaction.

This article has been extracted from M.D. Thesis. (Somayeh Barzanouni)
1. Introduction

One of the essential functions of using in vitro fertilization (IVF) techniques is to raise the possibility of having a healthy child in couples who are in danger of having a child with a genetic disease (1, 2). To accomplish this, before embryo implantation in the uterus, the genetic health of the embryo produced in laboratory conditions is examined using preimplantation genetic diagnosis (PGD). The embryo is then transferred to the uterus after assuring genetic health (1-4).

The common method of PGD implementation includes controlled ovarian stimulation, egg acquisition, intracytoplasmic sperm injection in the egg, keeping the embryos in a culture medium, detachment of 1 cell from an embryo on day 3 or a few cells on day 5 for genetic diagnosis, performing the necessary tests to diagnose, and finally selecting an embryo without disease and transferring it to the uterus (4-6). This method, unlike other diagnostic methods, does not cause complications that may lead to termination of pregnancy (3). However, this method of PGD, due to cell separation from the embryo, is a kind of invasive method so it can cause abortion after implantation (7, 8). Recently, 2 noninvasive methods for implementing PGD for obtaining embryo genetic material have been introduced, including PGD using blastocyst fluid and PGD using embryo culture medium (7-11). In both approaches, the required embryonic DNA is obtained from matters discarded after implantation in the uterus. The main drawback of both approaches is access to a small amount of genetic material in the embryo, making the performance of genetic studies difficult (7, 9). According to a study, it was estimated that 80 ± 70 and 99 ± 113 pg of DNA were present in the medium on day 3 and day 5/6, respectively. The study showed that with this amount of DNA, the TBC1 domain family member 3 gene, which is located on chromosome 17, could be identified, but it was not enough to accurately identify the testis-specific protein Y-linked 1 gene, which is located on the Y chromosome (12). It was reported that combining the amount of DNA obtained from both methods is sufficient for whole genome amplification and accurate aneuploidy screening (9).

Due to medical reasons, gender selection is defined as preventing childbirth with a severe genetic disorder (13, 14). PGD was initially introduced for selecting female embryos concerning chromosome X-related disorders (5, 14, 15). Although, currently, some families, due to several issues such as having multiple children of the same sex and wanting to have a child of different gender, request IVF implementation and pre-implantation genetic diagnosis (16).

This prospective clinical trial study attempted to determine the gender of embryos formed in the laboratory on day 5, using embryonic DNA extraction from the culture medium, and evaluation of the sex-determining region Y (SRY) and fragile X mental retardation (FMR1) genes for diagnosis of the Y and X chromosomes, respectively, using the polymerase chain
reaction (PCR) technique (17-19). Then, after the diagnosis of the gender of implanted embryos, in the 4th month of pregnancy the accuracy of this method was evaluated by ultrasound.

2. Material and Methods

2.1. Sample collection and preparation

This study was performed between December 2018 and March 2020 in Imam Khomeyni hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

According to the Cochran test, the minimum number of embryos required was 23. Due to the possibility of losing samples during the study, 30 samples were examined in the study.

\[ n = \frac{N z^2 pq}{N d^2 + z^2 pq} = \frac{30 \times 1.96^2 \times 0.5 \times 0.5}{30 \times 0.1^2 + 1.96^2 \times 0.5 \times 0.5} = 23 \]

The inclusion criteria were couples referred to the fertility clinic of Imam Khomeyni hospital for infertility and seeking assisted reproductive technology and IVF assistance using PGD for determining the gender of embryos, with female partners < 35 yr old.

The exclusion criteria were couples with cancelled cooperation, unsuccessful IVF, and no pregnancy or abortion before the 4th month of pregnancy. If the IVF was unsuccessful or the pregnancy was terminated before birth, a new couple was substituted.

Couples underwent transvaginal oocyte retrieval and fertilization using intracytoplasmic sperm injection. Following the intracytoplasmic sperm injection, fertilized oocytes were cultured in G-TL™ media (Vitrolife, Sweden) at 37°C with 6% CO₂ and 5% O₂. A total of 30 preimplantation embryos (calculated based on Cochran test) at day 5 were examined. After the embryo was removed, 20 μl of media was recovered from each day 5 embryo culture and transferred to DNA-free/DNase-free tubes under sterile conditions. DNA extraction and amplification were performed using the REPLI-g Single Cell Kit (QIAGEN, Netherlands) following the manufacturer’s protocol. The amplification product was quantified with nanodrop. Finally, the samples were stocked at 4°C until PCR.

2.2. PCR assay

The primers of the SRY and FMR1 genes were designed using NCBI Primer-Blast (Table I). PCR was performed based on the table II steps (according to the manufacturer’s protocol) in a thermal cycler (Perkin Elmer 480). Electrophoresis of the PCR products was performed on 1.5% agarose gels for 60 min. The gel was then stained with ethidium bromide and observed under a UV transilluminator. Then, according to the following 4 states, the blastocysts’ gender was predicted.

SRY⁺ / FMR1⁺, blastocyst has both X and Y chromosomes, blastocyst gender should be male.

SRY⁻ / FMR1⁺, blastocyst has only an X chromosome, blastocyst gender should be female.

SRY⁺ / FMR1⁻, blastocyst has only a Y chromosome, maybe blastocyst has aneuploidy, the test should be repeated.

SRY⁻ / FMR1⁻, blastocyst has neither X nor Y chromosomes, the test should be repeated.
Table I. Designed primers for SRY and FMRP genes

| Gene name | Product length | Primer type | Sequence (5’→3’) | Length | Tm | GC% | Self-complementarity |
|-----------|---------------|-------------|------------------|--------|----|-----|---------------------|
| SRY       | 230           | Forward     | CGCATTTCATCGTGTTCTC | 20     | 59.35 | 55.00 | 2                   |
|           |               | Reverse     | AATTCTCGGCAGCATCTTCG | 21     | 59.33 | 47.62 | 5                   |
| FMR1      | 302           | Forward     | GAGATGACCAGTGTGTCGAT | 22     | 59.96 | 50.00 | 3                   |
|           |               | Reverse     | CGCAGCGGACGTACCTTCAC | 19     | 60.81 | 63.16 | 4                   |

SRY: Sex-determining region Y, FMR1: Fragile X mental retardation, Tm: Primer melting temperature, GC%: Guanine cytosine nucleotides percentage in primer

Table II. PCR program

| Stage                        | Temperature (ºC) | Time (sec) |
|------------------------------|------------------|------------|
| Polymerase activation/denaturation | 94               | 120        |
|                               | 94               | 15         |
| Amplification (35 cycles)     | 58               | 20         |
|                               | 72               | 20         |
| Final extension               | 72               | 600        |

PCR: Polymerase chain reaction

2.3. Ethical considerations

In this prospective study, all the clinical information was obtained from the Fertility, Infertility Private Center. All participating couples completed the informed consent form. The clinical analysis was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (Code: IR.AJUMS.REC.1398.990).

3. Results

In this study, 117 couples participated, of which 54 became pregnant. Finally, in 30 pregnancies, the sex of the fetus was determined by ultrasound, and all pregnancies were successful, and the baby was born alive.

The SRY and FMR1 genes were successfully amplified in a day 5 culture medium and detected with bands at 230 bp and 301 bp, respectively. Positive controls (male and female DNA) were included in the PCR reactions. If PCR products were observed at both 230 bp and 301 bp, this result indicated that the DNA originated from a male sample. However, if samples originated from a female, a single PCR product at 301 bp was observed (Figure 1).

Analysis of the PCR products showed that out of the 30 embryos studied, 7 were male, and 23 were female. However, an ultrasound revealed that 13 fetuses were male and 17 were female. Thus, in 6 male embryos, the Y chromosome was not detected by the amplified SRY gene, and sex determination was incorrect. The calculation of the sensitivity, specificity, and diagnostic accuracy of this method was done based on the ‘2 by 2 table’ and the results were as follows (Table III):
Specificity (%) = \frac{\text{Number of true negatives}}{\text{Number of true negatives} + \text{Number of false positives}} \times 100
\quad = \frac{17}{17} \times 100 = 100

Positive predictive value (%) = \frac{\text{Number of true positives}}{\text{Number of true positives} + \text{Number of false positives}} \times 100
\quad = \frac{7}{7} \times 100 = 100

Negative predictive value (%) = \frac{\text{Number of true negatives}}{\text{Number of true negatives} + \text{Number of false negatives}} \times 100
\quad = \frac{17}{23} \times 100 = 73.9

Table III. The results of ‘2 by 2 table’

| PCR test result | Ultrasound result |
|-----------------|------------------|
| Male gender (+) | Male gender (+)  |
| Female gender (-)| Female gender (-)|
| 7 (TP)          | 0 (FP)           |
| 6 (FN)          | 17 (TN)          |

PCR: Polymerase chain reaction, TP: True positive, FP: False positive, FN: False negative, TN: True negative

4. Discussion

In this study, using embryo DNA extracted from the fetal culture medium on day 5, the authors tried to determine the presence or absence of a Y chromosome for gender determination of the studied embryo, and the sensitivity of this method was examined after the gender determination of embryos by ultrasound in the 4th month of pregnancy. The results demonstrated that despite the easy diagnosis of the X chromosome by the \textit{FMR1} gene, the Y chromosome diagnosis by the \textit{SRY} gene was not as easy, so that the PCR studies identified only 7 embryos with a Y chromosome, while the ultrasound results showed the existence of 13 boys.
As a result, it can be said that although the gender of all 7 cases diagnosed by ultrasound was the same as found in the culture medium, the gender of the diagnosed girls had an accuracy of 74%. So, in case a male gender is desired, we can trust the method to determine the gender of the embryo. However, if the preferred gender is female, it should be considered that 26% of the cases diagnosed as females using this method are probably males.

One of the factors that can explain this result is the differences in the size and dimensions of the 2 chromosomes X and Y. The Y chromosome is one of the smallest human chromosomes with approximately 57.23 nucleotides, and the SRY gene, located at the Yp11.2 locus, comprises only 828 nucleotides. In contrast, the X chromosome is about 156.05 Mbp long (2.72 times the Y chromosome), and the FMR1 gene, located at locus Xq27.3, has 46,135 nucleotides (about 55.71 times larger than the SRY gene).

A previous study used multiplex PCR for the detection of SRY (as a Y chromosome gene) and ALT1 genes (as a control). This study was performed on DNA extracted from blood cells. Its purpose was to evaluate the efficiency of the multiplex PCR technique and the sensitivity of the SRY gene to detect the male gender (18).

Another study reported that the use of cell-free DNA in the culture medium may be a viable alternative to the use of embryonic cell DNA for the diagnosis of a-thalassemia-SEA (20). The study evaluated the amount of cell-free DNA in the culture medium from the culture on day 3 and day 5, and reported that it was better to use the day 5 medium due to the higher amount of cell-free DNA.

Furthermore, Li et al. showed that cell-free DNA in a culture medium or fetal blastocyst fluid could be used to assess genetic and chromosomal defects. However, the amount of DNA obtained from these methods is small, and it may be necessary to use both ways together (7).

According to Yang et al., the amount of cell-free DNA in the day 3 embryonic culture medium was insufficient to detect the Y chromosome by the SRY gene, and it was recommended to use the day 5 embryonic culture medium (8).

Given the huge difference in the dimensions of these 2 chromosomes, it is clear that the extraction of the Y chromosome and the study of its genes is more difficult than the extraction and study of the genes of the X chromosome, particularly in the extraction of an embryo’s genetic material from the culture medium where the amount of DNA obtained for examination is small.

Our findings are consistent with a study that showed that the amount of DNA obtained from culture media was not sufficient for accurately detecting the testis-specific protein Y-linked 1 gene, which is located on the Y chromosome, but was enough for detecting the TBC1 domain family member 3 gene, which is located on chromosome 17 (12).

5. Conclusion

The findings of this study suggest that simultaneous extraction of fetal DNA from the blastocyst fluid and from the embryo culture medium enhances the amount of fetal DNA obtained for examinations. Also, for increasing the accuracy of Y chromosome detection and
detecting the SRY gene, some of the unique sequences of this chromosome should be examined simultaneously using the multiplex PCR technique.

Acknowledgements

This work was supported by grants from the Infertility Center, Imam Khomeini hospital, Ahvaz Jundishapur University of Medical Sciences, Khuzestan, Iran.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

[1] Basille C, Frydman R, El Aly A, Hesters L, Fanchin R, Tachdjian G, et al. Preimplantation genetic diagnosis: State of the art. *Eur J Obstet Gynecol Reprod Biol* 2009; 145: 9-13.

[2] Tasca RJ, McClure ME. The emerging technology and application of preimplantation genetic diagnosis. *J Law Med Ethics* 1998; 26: 7-16.

[3] Baruch S, Javitt G, Scott J, Hudson K. Preimplantation genetic diagnosis: A discussion of challenges, concerns, and preliminary policy options related to the genetic testing of human embryos. USA: Genetics and Public Policy Center; 2004.

[4] Harper JC, SenGupta SB. Preimplantation genetic diagnosis: State of the art. *Hum Genet* 2012; 131: 175-186.

[5] Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. *Nature* 1990; 344: 768-770.

[6] Handyside AH, Penketh R, Winston R, Pattinson J, Delhanty J, Tuddenham E. Biopsy of human preimplantation embryos and sexing by DNA amplification. *Lancet* 1989; 333: 347-349.

[7] Li P, Song Z, Yao Y, Huang T, Mao R, Huang J, et al. Preimplantation genetic screening with spent culture medium/blastocele fluid for in vitro fertilization. *Sci Rep* 2018; 8: 1-10.

[8] Yang L, Lv Q, Chen W, Sun J, Wu Y, Wang Y, et al. Presence of embryonic DNA in culture medium. *Oncotarget* 2017; 8: 67805-67809.

[9] Kuznyetsov V, Madjunkova S, Antes R, Abramov R, Motamed G, Ibarrientos Z, et al. Evaluation of a novel non-invasive preimplantation genetic screening approach. *PLoS One* 2018; 13: e0197262.

[10] Petersen CG, Mauri AL, Vagnini LD, Renzi A, Petersen B, Matilla MC, et al. Randomized comparison of two commercial culture media (Cook and Vitrolife) for embryo culture after IMSI. *JBRA Assist Reprod* 2019; 23: 33-36.

[11] Vera-Rodriguez M, Diez-Juan A, Jimenez-Almazan J, Martinez S, Navarro R, Peinado V, et al. Origin and composition of cell-free DNA in spent medium from human embryo culture during preimplantation development. *Hum Reprod* 2018; 33: 745-756.

[12] Galluzzi L, Palini S, De Stefani S, Andreoni F, Primiterra M, Diotallevi A, et al. Extracellular embryo genomic DNA and its potential for genotyping applications. *Future Sci OA* 2015; 1: FS062.

[13] Ethics Committee of the American Society of Reproductive Medicine. Sex selection and preimplantation genetic diagnosis. *Fertil Steril* 2004; 82 (Suppl.): S245-S248.

[14] Rajan-Babu I-Sh, Lian M, Cheah FSH, Chen M, Tan ASC, Prasath EB, et al. FMR1 CGG repeat expansion mutation detection and linked haplotype analysis for reliable and accurate preimplantation genetic diagnosis of fragile X syndrome. *Expert Rev Mol Med* 2017; 19: e10.

[15] Handyside AH, Lesko JG, Tarín JJ, Winston RM, Hughes MR. Birth of a normal girl after in vitro fertilization and preimplantation diagnostic testing for cystic fibrosis. *N Engl J Med* 1992; 327: 905-909.

[16] Meseguer M, Garrido N, Remohí J, Simón C, Pellicer A. Gender selection: Ethical, scientific, legal, and practical issues. *J Assist Reprod Genet* 2002; 19: 443-446.
[17] Joshi BD, De R, Goyal SP. Utility and applicability of a universal set of primers in identifying the sex of South and Southeast Asian mammals. Zool Stud 2019; 58: e19.

[18] Osman J, Murad NAA, Chin SF, Jamal R. Highly sensitive and reliable human sex determination using multiplex PCR. Asia-Pacific J Mol Med 2016; 4: 1.

[19] Settin A, Elsobky E, Hammad A, Al-Erany A. Rapid sex determination using PCR technique compared to classic cytogenetics. Int J Health Sci 2008; 2: 49-52.

[20] Wu H, Ding C, Shen X, Wang J, Li R, Cai B, et al. Medium-based noninvasive preimplantation genetic diagnosis for human α-thalassemias-SEA. Medicine 2015; 94: e669.